US Patent

US12358861 — Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Method of Use · Assigned to Orphalan SA · Expires 2039-05-03 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a new crystalline form of triethylenetetramine tetrahydrochloride with improved stability, useful in treating Wilson's disease.

USPTO Abstract

The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm −1 . The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4262 — trientine-tetrahydrochloride

Patent Metadata

Patent number
US12358861
Jurisdiction
US
Classification
Method of Use
Expires
2039-05-03
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Orphalan SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.